These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 35930018)

  • 21. [New blood glucose-lowering drugs in type 2 diabetes: a review of the literature].
    Kleefstra N; van Hateren KJ; Houweling ST; Verhoeven S; Kooy A; Goudswaard AN; Bilo HJ
    Ned Tijdschr Geneeskd; 2010; 154():A886. PubMed ID: 20298625
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.
    Yang W; Liu J; Shan Z; Tian H; Zhou Z; Ji Q; Weng J; Jia W; Lu J; Liu J; Xu Y; Yang Z; Chen W
    Lancet Diabetes Endocrinol; 2014 Jan; 2(1):46-55. PubMed ID: 24622668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comparison of acarbose and metformin therapy in newly diagnosed type 2 diabetic patients with overweight and/or obesity.
    Sun W; Zeng C; Liao L; Chen J; Wang Y
    Curr Med Res Opin; 2016 Aug; 32(8):1389-96. PubMed ID: 27052634
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis.
    Liao X; Song L; Zeng B; Liu B; Qiu Y; Qu H; Zheng Y; Long M; Zhou H; Wang Y; Du Y; Xu J; Shen R; Tong Q; Cai L; Li X; Guo S; Yang G; Zhu Z; Pu X; Wei H; Zheng H
    EBioMedicine; 2019 Jun; 44():665-674. PubMed ID: 30922964
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus.
    Su B; Liu H; Li J; Sunli Y; Liu B; Liu D; Zhang P; Meng X
    J Diabetes; 2015 Sep; 7(5):729-39. PubMed ID: 25327485
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of vildagliptin compared with glibenclamide on glucose variability after a submaximal exercise test in patients with type 2 diabetes: study protocol for a randomized controlled trial, DIABEX VILDA.
    Fofonka A; Ribeiro JP; Casali KR; Schaan BD
    Trials; 2014 Nov; 15():424. PubMed ID: 25366037
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of Non-insulin Anti-hyperglycemic Agents on Gut Microbiota: A Systematic Review on Human and Animal Studies.
    Cao TTB; Wu KC; Hsu JL; Chang CS; Chou C; Lin CY; Liao YM; Lin PC; Yang LY; Lin HW
    Front Endocrinol (Lausanne); 2020; 11():573891. PubMed ID: 33071980
    [No Abstract]   [Full Text] [Related]  

  • 30. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
    DeFronzo RA; Buse JB; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetologia; 2016 Aug; 59(8):1645-54. PubMed ID: 27216492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors that influence the efficacy of acarbose and metformin as initial therapy in Chinese patients with newly diagnosed type 2 diabetes: a subanalysis of the MARCH trial.
    Zhang J; Wang N; Xing X; Yang Z; Wang X; Yang W
    Curr Med Res Opin; 2016; 32(4):713-9. PubMed ID: 26714411
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improvement in glucose tolerance and insulin sensitivity by probiotic strains of Indian gut origin in high-fat diet-fed C57BL/6J mice.
    Balakumar M; Prabhu D; Sathishkumar C; Prabu P; Rokana N; Kumar R; Raghavan S; Soundarajan A; Grover S; Batish VK; Mohan V; Balasubramanyam M
    Eur J Nutr; 2018 Feb; 57(1):279-295. PubMed ID: 27757592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus.
    Napolitano A; Miller S; Nicholls AW; Baker D; Van Horn S; Thomas E; Rajpal D; Spivak A; Brown JR; Nunez DJ
    PLoS One; 2014; 9(7):e100778. PubMed ID: 24988476
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Crosstalk between glucagon-like peptide 1 and gut microbiota in metabolic diseases.
    Zeng Y; Wu Y; Zhang Q; Xiao X
    mBio; 2024 Jan; 15(1):e0203223. PubMed ID: 38055342
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Randomised cross-over trial of vildagliptin and pioglitazone as add-on therapy in patients with type 2 diabetes: predicting Which One is Right Here (WORTH) study protocol.
    Yeu RQ; Brandon R; Jiang Y; Griffiths D; Smallman K; Moffitt A; Doherty G; Paul R; Harré Hindmarsh J; Merriman TR; Macaskill-Smith K; Orr-Walker B; Murphy R
    BMJ Open; 2020 Sep; 10(9):e036518. PubMed ID: 32873667
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes.
    Dalsgaard NB; Gasbjerg LS; Hansen LS; Hansen NL; Stensen S; Hartmann B; Rehfeld JF; Holst JJ; Vilsbøll T; Knop FK
    Eur J Endocrinol; 2021 Mar; 184(3):383-394. PubMed ID: 33449919
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects.
    DeLeon MJ; Chandurkar V; Albert SG; Mooradian AD
    Diabetes Res Clin Pract; 2002 May; 56(2):101-6. PubMed ID: 11891017
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.